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 The Collaborative Pediatric Critical Care Research Network has 
trialed several versions of the NIH mandated single IRB model in 
hopes to find the most efficient model. Study startup milestones were 
measured over four trials comparing the proficiency of the different 
versions. The biggest source of delay surrounds the complexity of an 
institution ceding implementation and review to another institution. 
Time and communication with key individuals is required to acclimate 
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Considerations for Academic Medical Centers Relying on a 
Central Institutional Review Board 
Chapter 1: Introduction 
Improving clinical trial efficiency has been a common goal 
among research organizations, and much attention has been 
specifically focused on multi-center clinical trial start-up periods.  
There are several phases included in a clinical trial start-up period, 
including the protocol design and scientific peer review; the process to 
apply for and secure funding and resources; review by institutional 
Human Research Protection Programs (HRPPs), including Institutional 
Review Board (IRB) review, Conflict of Interest review, and other 
ancillary reviews; database creation; and recruitment of participants to 
secure enrollment.  The use of single or Central IRBs (CIRB) has been 
posited as one method for increasing efficiency; however, when using 
a CIRB, it is important to consider how the other phases of the clinical 
trial start-up period are affected and can be optimized.   
Centralization of the IRB process requires resources for 
managing submission to the CIRB and meeting the remaining local 
HRPP review requirements at each participating site.  This may be 
accommodated through centralization of an administrative group 
between the CIRB and the participating sites, often titled a CIRB 




positioned to assist throughout the clinical trial start-up period, 




phase.  Centralization of such an administrative group requires a 
standardized procedure and workflow to ensure that efficient timelines 
for protocol development, CIRB submission and approval, and initiation 
of enrollment are maintained.   
In 2012 the Collaborative Pediatric Critical Care Research 
Network (CPCCRN) and the University of Utah partnered to develop a 
CIRB process, a centralized administrative group, and a standardized 
procedure and workflow for clinical trial start-up for all research 
performed by CPCCRN.  The CPCCRN Data Coordinating Center (DCC) 
assumed responsibility for this new procedure and workflow and 
became the centralized administrative group.  More recently, the 
University of Utah was awarded by the National Center to Advance 
Translational Science (NCATS) to be a Trial Innovation Center (TIC) for 
the Trial Innovation network (TIN).  One of the services that these 
TICs are offering is single IRB support for multi-institutional research 
projects and networks.  A new partnership with this group was formed 
to further standardize and enhance the efficiency of this CIRB 
procedure. 
Chapter 2: Background 
In the past few decades, multicenter trials have become the new 




the scientific rigor or external validity required to support widespread 
changes in practice.1  The Nation1al Institutes of Health (NIH) supports 
a variety of research networks fostering investigator-initiated 
multicenter clinical trials.  As of June 21, 2016, the NIH released their 
final policy on the Use of a CIRB for Multi-Site Research.  Newly 
funded PI’s of multi-center studies are now expected to rely on a 
single IRB. This CIRB model is charged to carry out the functions that 
are required for institutional compliance with IRB review set forth in 
HHS regulations at 45 CFR 46.2  A DCC that has expertise in handling 
all CIRB functions is critical since many investigators have very little 
experience working with and submitting their research to a CIRB (NIH, 
2016).  Little guidance is available in the peer-reviewed literature on 
the use of CIRBs for multicenter trials.3  This capstone project will 
objectively outline the challenges and obstacles multi-institutional 
sponsored projects or research networks encounter when adhering to 
National Institute of Health (NIH) policy on central IRB.  The goal of 
the project is to identify clearly, what issues are faced when making 
                                                          
1 Bellomo, R., 2009. Why We Should be Wary of Single-Center Trials. 
Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/19789447 
2 NIH, June 21, 2016. Final NIH Policy on the Use of a Single 
Institutional Review Board for Multi-Site Research. Retrieved from: 
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-094.html 
3 Check, D. K., 2013. Use of central institutional review boards for 
multicenter clinical trials in the United States: a review of the literature. 





the transition from local IRB review to CIRB review.  A final goal of the 
project is to ascertain what processes were most effective in easing 
the burden of this transition and how they can help others planning on 
this transition in the future.  The University of Utah IRB and Utah DCC 
have collaborated to create a CIRB of record for the CPCCRN.   
Established in 2005, the CPCCRN consists of a team of eight 
academic clinical sites and a data coordinating center, as well as the 
Eunice Kennedy Shriver National Institute of Child Health and Human 
Development (NICHD).  This network seeks to reduce morbidity and 
mortality in pediatric critical illness and injury and to establish a 
framework for developing the scientific basis for pediatric critical care 
practice.  These goals cannot be achieved without the support of 
collaborative clinical trials otherwise impracticable in single 
institutions.4  Research concepts are proposed and vetted through the 
network Steering Committee for approval, development, and 
implementation.  When a final protocol has been scheduled for 
implementation, it is the responsibility of the DCC to make any agreed 
upon modifications and to distribute the protocol to network members.  
The DCC is then responsible for preparing the CIRB submission on 
                                                          
4 Wilson, D. F., 2006. Collaborative Pediatric Critical Care Research 






behalf of the network.  DCC project managers are experienced in 
preparing IRB applications and handling all aspects of IRB regulatory 
work on behalf of the investigator.   
Prior to instituting the CIRB, the CPCCRN had done well during 
its first ten years in obtaining IRB approvals expeditiously.  A rotating 
IRB model was used from the beginning of the network.  The lead site 
would submit first to their IRB, making any adjustments required by 
their local IRB.  Once the lead site had obtained approval, all sites 
would submit to their respective IRB’s using the lead sites approved 
IRB application as a template.  Use of a CIRB in the network began as 
an experiment to proactively comply with what the network expected 
to be a requirement in the near future from NIH and the proposed 
changes to the Common Rule.  In addition, this decision was based on 
the fact that several network RFAs required network sites to use a 
central IRB.  In addition, several federally sponsored meetings to 
“discuss” IRB models appeared to be meetings preparatory to 
requiring CIRB implementation.  Initially, seven of the eight network 
sites had agreed to voluntarily rely on the Utah CIRB.  One CPCCRN 
site declined participation, waiting until the requirement to use a CIRB 
became mandatory.  The University of Utah CIRB experiment that 
began in 2013 has introduced different challenges, which will be 




liaison from the DCC to the Utah TIC has affected the challenges with 
new standardized procedures. 
    The DCC is a research facility located at the University of Utah that 
serves as the central biostatistical and logistical resource for the work 
of the CPCCRN.  The DCC has experience with the coordination of 
multicenter clinical trials, and expertise in study design, clinical data 
management, IT solutions, and biostatistical analysis.   In short, the 
DCC scope of activities includes assuring the successful execution of all 
scientific and administrative activities carried out by the Network, in 
collaboration with the NICHD, Steering Committee and Advisory Board.  
With the Utah TIC managing the CIRB process the DCC will supervise 
their effort to support the CPCCRN. 
 The University of Utah Human Research Protection Program is a 
complex biomedical and social behavioral enterprise with more than 
5,000 active studies.  The HRPP has maintained full accreditation from 
the Association for the Accreditation of Human Research Protection 
Programs (AAHRPP) since 2007.  The IRB is comprised of seven review 
panels with over 100 members that meet up to three times per week 
in order to conduct thorough and timely reviews.  The University acts 
as the IRB of record for the Veterans Affairs Salt Lake City Health Care 
System (VA) and Primary Children’s Hospital (PCH), as well as many 




community partners.  The HRPP has been managed by an automated, 
web-based system since 2006.  The Electronic Research Integrity and 
Compliance Administration (ERICA) System allows HRPP members, 
including study teams, 24-hour access from any location with an 
internet connection to manage existing projects, submit new projects, 
and complete a wide variety of other tasks. 
     
Chapter 3: Methodology 
Challenges and obstacles for creating a multi-institutional compliance 
with NIH policy on central IRB  
Implementing the CIRB process for CPCCRN was done in 
incremental steps.  In spring 2012, the DCC PI posed the idea of 
creating a CIRB for the Network in conjunction with the proposed 
changes to the Common Rule.  At that time, the Network consisted of 
seven Clinical Centers and eight sites. Each Clinical Center PI was 
tasked with opening a dialogue with their respective IRBs.  
A reliance agreement is a written document that allows an 
institution to delegate the responsibilities of an IRB to a central IRB for 
the purpose of central management of multi-center studies (See 
Appendix A).  These agreements are negotiated on a site-by-site basis 




the CIRB process.  Once a reliance agreement is in place, the site may 
rely upon that particular CIRB for any study between the institution 
and the same CIRB. During the initiation of the CIRB for CPCCRN, the 
process of getting these Reliance agreements in place took nearly a 
year.  As the familiarity with Reliance Agreements has become more 
common, the timeline to obtain these agreements has generally 
decreased. 
In late summer of 2012, negotiations for IRB reliance 
agreements began.  Phoenix Children’s Hospital signed the first 
agreement in November 2012. Other sites quickly followed.  By May 
2013, six sites had Reliance Agreements.  An additional site’s Reliance 
Agreement was executed in November 2013.  In December of 2014, 
CPCCRN’s grant cycle renewed; four sites were dismissed and four 
sites joined.  Reliance Agreements for the four new sites were 
executed by February of 2015. 
Following the decision to allow the Utah TIC to support CIRB 
functions for the network. The NCATS and TICs implemented a 
standard reliance agreement known as The SMART IRB Reliance 
Agreement (See Appendix B).5  This standardized agreement 
                                                          
5 SMART, 2017. SMART IRB Homepage. Retrieved from: 





streamlines the need to negotiate on a site-by-site basis since it 
requires all sites to follow the same procedures and policies operating 
multi-site research under NIH guidance.  Throughout the period of this 
capstone, seven of the eight sites have signed this agreement.  With 
only one site that is owned by a private entity not signing to date.   
After all participating sites have executed reliance agreements 
and the DCC’s IRB becomes the CIRB, the data coordination center 
submits a study application to the DCC’s IRB on behalf of all the sites.  
The study application includes information about each of the 
participating sites and may include site-specific documents and 
consent forms.  Once a study has CIRB approval, the study is 
effectively approved at all sites.  Within CPCCRN, this application 
process has become more efficient thanks to the development of a 
standard Working Guideline. This working guideline contains consistent 
language and responses to questions asked in the CIRB application.  
These efficiencies benefit both the DCC staff submitting the application 
and the CIRB staff reviewing the application, resulting in shorter 
review times and faster CIRB study approvals. 
Issues institutions face when making the transition from a local IRB 




Due to differences in state law and institutional practices, a good 
portion of consent language must be site-specific.  Originally, in the 
CIRB process, sites completed their own consent documents, often 
requiring DCC staff to edit the same document and return it back to 
the site again for approval.  This process resulted in multiple steps to 
arrive at a final draft.  As a first attempt to minimize this effort, DCC 
staff locked certain sections of the consent forms, leaving other 
sections available for sites to edit for local requirements.  However, 
this presented new issues with formatting and resulted in more back-
and-forth.  Finally, the current process with pre-approved, site-specific 
informed consent templates was developed which minimized the 
roadblock of the back-and-forth communication between the site and 
the CIRB.  The template for each site contains the site’s IRB-required 
standard language and is pre-approved by the site’s IRB prior to the 
study application.  When a new study is developed, the DCC adds 
study-specific information to the site-specific consent templates and 
submits the documents to the CIRB along with the study application.  
Utilizing these templates has improved timelines for the CIRB process. 
Local review is a term used to describe site-level IRB approval of 
a CIRB submission.  Local reviews occur after a reliance agreement 
has been executed and are not intended to be a full IRB review, as 




the local review is to ensure that any local requirements, such as 
conflict of interest or any ancillary reviews related to the study are met 
by the CIRB submission.  Once the CIRB application is approved and a 
local review is completed by the site, the study is approved for 
enrollment at the site. 
Finally, an additional innovation added the process by the NCATS 
TIC initiative included adding an online platform that allows the relying 
sites and the IRB of record or reviewing IRB to exchange information 
and communicate.  Here, actions are documented and standardized for 
all sites using the SMART IRB reliance agreement.  This allows IRBs to 
identify who is the IRB of record and who the relying sites are. Relying 
sites can cede review for every project they are invited to participate 
in, relying sites can provide a profile of their institution, and local 
requirements that the IRB of record needs to know. The exchange 
provides a location for documentation that local review has been 
completed and interchange submission approvals and documents such 
as informed consents or surveys across the network or multi-
institutional trial.6 
     
                                                          






Chapter 4: Anticipated Results and Outcomes 
The effectiveness of processes used to achieve the transition  
Early in the CIRB process, the DCC prepared would prepare an 
Informed Consent document for the study as a template, including all 
science and procedural information.  This Informed Consent template 
was then sent to the site to include the site’s locally required 
language.  This process necessitated a lot of back and forth with the 
site, culminating in weeks of delay.  It was discovered that some of 
the sites' IRBs had specific preferences that contradicted the CIRB's 
requirements, such as the required footer or header information.  This 
led to the development of site-approved consent templates, which 
included all locally required information.  The DCC uses these 
templates to insert the science and procedural information and the 
consent is ready for submission. 
 Another challenge encountered by the DCC was in how the 
applications (original, amendment, continuing review) were being 
assigned and reviewed by the Utah IRB staff.  IRB reviewer 
assignments are made by the day the application is submitted.  This 
resulted in many different IRB staff reviewing the DCC’s CIRB 
submissions.  Due to this, the DCC struggled with varying requests for 




CIRB submissions.  Once this challenge was identified, the DCC had a 
face-to-face meeting with all key players between the DCC and IRB 
staff.  This resulted in creating an open dialogue between our 
institutions and provided clarity on some of the issues at hand. 
 Since the network already had an efficient IRB submission 
process, the DCC collected time and effort data on the new method of 
submitting to a CIRB.  It is important to evaluate which submission 
method is more efficient for the network, the rotating model of 
submitting the lead site first with all other sites following or submission 
to a single IRB.  DCC Project Managers were assigned to collect 
various data points to answer this question.  This data was collected 
for three years.  Data was collected the following data on each study 
involving the CIRB: the date each site was approved to submit to their 
local IRB, the date each site actually submitted to their local IRB, the 
date each site received IRB approval, number of days from time to 
submission to approval, the date each site was approved to begin 
enrolling and the date of each site’s first enrollment.  These data were 
collected for the original IRB/CIRB submission.  Similar data were 
tracked for amendments and continuing reviews, which are not 
discussed in this project.  Performance metrics for the first five CIRB 
studies are presented in Table 1. These data highlight that the Utah 




protocol submission and CIRB approval.  Overall, five protocols were 
reviewed on behalf of twenty-eight sites.  Following CIRB approval, on 
average it took 80.6 days to complete local HRPP before screening 
could begin.  This was recognized as an area needing improvement.  
The reason for this delay is primarily to do with local IRBs performing 
redundant IRB reviews in addition to HRPP local reviews.  With time, 



















 Below are tables that further break down the time spent on specific 
network project original submissions.  Data for tables 2 - 5 were 
collected from historical and real time milestones for sites participating 
in the specified CPCCRN projects. The data was documented and 
retrieved from IRB approval documents at the CIRB and local IRBs. 
The discussion of table data and site nuances includes details provided 
from the project managers assigned to those projects. Each table 
allows for some comparison between local submissions versus CIRB 
submission due to site variances of reliance on the CIRB at the time of 







Table 2: GIFT Study Startup Timeline by Site 
 
Blue: Days from original submission to IRB/CIRB approval. Orange/Green: Days 
from CIRB approval to local review approval (local review submission date is denoted 
by the line between orange/green). Brown/Purple: Days from local review approval 
to first enrolled subject. Contract execution date is denoted by the line between 
brown/purple. Yellow highlighted sites do not participate in the CIRB. 
GIFT was originally a single-center trial at Nationwide Children’s 
Hospital.  In 2014, the PI of GIFT was accepted into CPCCRN and 




CPCCRN sites.  The CIRB for this study included all CPCCRN sites, 
except for one.  The lead site, Nationwide Children’s Hospital opted to 
remain on their local IRB until formal NIGMS (funding agency) 
approval was granted.  Their local review application was submitted 
and approved the same day.  Due to the nature of the research, GIFT 
is a slow enrolling study.  Despite this, some sites took longer to begin 
















Table 3: PICqCPR Study Startup Timeline by Site 
 
Blue: Days from original submission to IRB/CIRB approval. Orange/Green: Days 
from CIRB approval to local review approval (local review submission date is denoted 
by the line between orange/green). Brown/Purple: Days from local review approval 
to first enrolled subject. Contract execution date is denoted by the line between 
brown/purple. Yellow highlighted sites do not participate in the CIRB. 
PICqCPR is a good project to demonstrate the difference between local 
and central review with roughly half the sites using local IRB review 




time for IRB review followed by a site-specific period of local review.  
Once a site has local review approval they are allowed to screen and 
enroll. Local IRB sites, highlighted in yellow, have a local review period 
followed directly by screening and enrolling and do not have a local 
review period.  It should be noted that the sites dominated by the 
color red were introduced to the study approximately two years after 
enrollment had begun for other sites.  The local review period for these 
sites began when approval to submit their local review was given 
rather than the CIRB approval that occurred two years prior.  These 
three sites took the longest to obtain local review approval due to 
PICqCPR being their first exposure to the CIRB model and time was 
needed to initiate reliance agreements.   Additionally, the DECH site 
was delayed in obtaining local review approval due to delays in 










Table 4: iNO Study Startup Timeline by Site 
 
Blue: Days from original submission to IRB/CIRB approval. Orange/Green: Days 
from CIRB approval to local review approval (local review submission date is denoted 
by the line between orange/green). Brown/Purple: Days from local review approval 
to first enrolled subject. Contract execution date is denoted by the line between 
brown/purple. Yellow highlighted sites do not participate in the CIRB. 
All but one of the sites participating in the iNO study relied upon the 
CIRB.  The site not participating in the CIRB (UPMC) submitted an 
application to their own IRB for full review and was able to receive 




CIRB approval.  Two CIRB sites (CHOM and DECH) had much longer 
local review approval times when compared to the other sites.  Delays 
at these sites were due to extra local administrative approval 
processes, which are in addition to local IRB reviews.  While these two 
sites had delays in approval, their time to first enrollment was shorter 
than the other sites.  As these sites waited for approval, they were 
able to train and prepare for the launch of the study.  Once approval 















Table 5: PHENOMS Study Startup by Site 
 
Blue: Days from original submission to IRB/CIRB approval. Orange/Green: Days 
from CIRB approval to local review approval (local review submission date is denoted 
by the line between orange/green). Brown/Purple: Days from local review approval 
to first enrolled subject. Contract execution date is denoted by the line between 
brown/purple. Yellow highlighted sites do not participate in the CIRB. 
There are currently nine clinical centers participating in PHENOMS, 
seven of which participate in the Utah CIRB.  On September 23, 2014, 
all CIRB participating sites were approved to submit the CIRB 




and/or approval. Based on the CIRB Paper Time Summary for 
PHENOMS Table, three sites (CHLA, CHOM, and CHOP) received study 
approval and enrolled their first subject within or less than 150 days.  
The IRBs at two sites (CNMC and NWCH) required a full submission 
even though the sites participate in and cede to the Utah CIRB.  As a 
result, for these two sites, the time from local review approval to the 
first subject enrolled was greater than 100 days.  Two other sites 
(MICH and UCLA) were not renewed as network sites.  In addition, 
both sites experienced staff turnover affecting time of the first subject 
enrolled.  Lastly, as evident from the Table, the time of approval to the 
first subject enrolled for non-CIRB participating sites (UPMC and 
WASH) was relatively shorter than CIRB participating sites; less than 
100 days. 
Chapter 5: Analysis 
Tables 1 - 5 and descriptions demonstrate that startup at 
multiple institutions is highly variable regardless of IRB model because 
of external factors not related to IRB review.  In general, at study 
startup, there is no compelling evidence that CIRB is faster than local 
review.  However, initial data collected for amendments and continuing 
reviews present persuasive evidence that the CIRB model is 
substantially faster than the local model. Although this data is not 




Lessons learned from the transition that can benefit other institutions 
Lessons learned from this project focus around the goal of 
standardizing agreements and processes.  Such as the SMART IRB and 
SMART IRB Exchange introduced by the NCATS TIC team.  In principle, 
once the SMART IRB agreements and SMART IRB Exchange platform 
are operational and all sites are trained and feel comfortable, it is 
highly likely that the process will be expedited and improve the 
timelines demonstrated through the initial projects presented in this 
project.   
Standardization across institutions in multi-center research will 
optimize speed and completion of the necessary tasks of startup.  
However, this project has identified several roadblocks to 
standardization.  Almost every institution has resisted agreeing to the 
standard SMART IRB Reliance Agreement.  The reasons for each site 
varies due to different policies and variances in legal counsel opinions 
from site to site.  This was overcome by improving communication 
between the involved legal parties at the site and from the SMART IRB 
agreement developers at Harvard. CIRB liaison involvement or site PI 
and research team participation proved to be ineffective at expediting 




 Based on site feedback, an additional roadblock to standardizing 
the process includes the SMART IRB Exchange platform meant to 
advance and improve review board communication and documentation 
transparency between network IRBs has proven to be even more 
challenging than the SMART IRB agreement. This is mainly due to the 
lack of formal training on the platform. Site IRBs and research teams 
never received any training or instruction from the NCATS TIC team. 
As a result, participation has been slow and uneven across all sites. 
This process is still underway in the CPCCRN despite efforts from 
NCATS TIC representatives and or DCC effort to educate sites. The 
best solution to date includes scheduling webinars with site research 
teams, site IRB representatives, CIRB representatives, NCATS TIC 
staff and DCC staff to train every one of the uses of the exchange and 
answer questions.   
Final obstacles to this standardization process, specific to 
CPCCRN, include the already functional CIRB process put in place by 
the DCC team prior to the NCATS TIC changes implemented more 
recently.  Because sites were used to the previous functional CIRB 
process, there has been major resistance to the NCATS changes that 
other networks and studies that did not have a CIRB process in place 
have seen.  As a result, CPCCRN sites have felt no urgency to 




prefer to follow old processes.  The saying “you cannot teach an old 
dog new tricks” strongly comes to play when making changes in a 
multi-institutional environment.  In this case, the best solution is to 
bolster sponsor support. NICHD support has required sites to transition 
to the NCATS changes. Even with sponsor guidance, the process 
continues at this time and full transition has not occurred for the 
CPCCRN. 
 In conclusion, the study startup period is compounded by many 
steps that extend beyond IRB review.   Whether the review is local or 
central, the work must be shifted from one site to another to manage 
the required task of study startup.  When complying with requirements 
to utilize central review for multi-institutional research, communication 
and education must be provided early and consistently throughout the 
transition and even after. Phone calls and face-to-face meetings 
extend the value of communication substantially more than simple 
email. Moreover, when standardizing these processes for multiple sites 
and networks, great patience is needed due to variances from site to 
site. Formal training for these standard procedures is optimum and 
leadership support is crucial to creating motivation at each site to 
implement new procedures.   
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Reliance Agreement Template 
RELIANCE AGREEMENT 
 
This agreement allows the University of Utah IRB (UIRB) to act as the IRB for an external 
institution or external investigator. The external institution or external investigator is not 
required to have a Federal-wide Assurance (FWA) in order to use this agreement.   
 
DIRECTIONS FOR USE OF THIS TEMPLATE: 
• This agreement should be signed by the external institution’s signatory official or by the 
external investigator, as applicable.  
• If the study is FDA regulated, the UIRB’s signatory official must also sign this agreement. 
• If the external institution or investigator has a FWA, the UIRB’s signatory official must 
also sign this agreement.  
• Instructions and text red font should be replaced or deleted. 
 
I. Purpose 
This Reliance Agreement sets forth the agreement between the University of Utah and 
<<insert name of external institution or investigator>> concerning the agreed upon 
arrangements between the same for the use of the University of Utah’s Registered 
Institutional Review Board (UIRB). 
• The University of Utah maintains Federal Wide Assurance Number FWA00003475 
assigned by the Office for Human Research Protections (OHRP). 
• <<Insert name of external institution>> maintains Federal Wide Assurance Number 
<<insert FWA number>> signed by OHRP. Delete this bullet if your institution does not 
maintain a FWA. 
This agreement concerns the reliance of <<insert name of external institution/investigator>> 
on the review and approval by the UIRB, as specified in this agreement. This agreement sets 
forth respective authorities, roles and responsibilities of each party in such arrangement.  
Those signing below agree that <<insert name of external institution/investigator>> may 
accept and rely on the review and approval by the UIRB of research involving human 
subjects as specified in this agreement. <<Insert name of external institution/investigator>> 
will abide by all determinations of the UIRB and will accept the final authority and decisions 






II. Types of Research Covered by this Agreement 
This agreement is limited to the following specific protocol(s): 
IRB Number: <<insert number>> 
Title of Study: <<insert title>> 
Principal Investigator: <<insert name>> 
Sponsor or Funding Agency: <<insert sponsor>> 
 
OR 
This agreement applies to human subject research that is <<describe they types of studies 
that will be covered in this agreement, e.g. studies regulated by the Food and Drug 
Administration (FDA), all studies conducted by the institution, all studies from a specific 
department, etc. >>. Only human subject research for which both UIRB and <<insert name 
of external institution/investigator>> have agreed that review will be ceded to the UIRB will 
be included in this agreement.  
 
Insert the following after the description of the types of research covered by the agreement: 
This agreement does not preclude <<insert name of external institution/investigator>> from 
taking part in research not covered by this agreement. 
 
III. Compliance with Federal Agency Guidance 
This agreement meets federal requirements for designation of another institution’s IRB as 
the reviewing IRB, as set forth in guidance issued by the Office for Human Research 
Protections (OHRP) entitled, Terms of the Federalwide Assurance (current as of June 17, 
2011).  
 
IV. Compliance with Federal and State Law and University of Utah Policy 
Review and approval of human subject research under this agreement shall be conducted in 
compliance with the federal regulations as codified in 45 CFR 46 and 21 CFR 50 & 56 (as 
applicable), other pertinent  federal regulations, state and local laws, and all applicable 
University of Utah policies pertaining to the protection of human subjects participating in 
research. 
 
V. Informed Consent 
Research subject to this agreement must employ a consent process, including a consent 
form, except when a waiver of informed consent is approved by the UIRB according to 45 




Consent Template for use for research specified in this agreement. Modifications will be 
expected as to customize the form for the external site. Modifications will be subject to 
approval by the UIRB. <<Insert name of external institution/investigator>>, when 
responsible for enrolling subjects, will obtain, document and maintain records of informed 
consent for each such subject or each subjects legally authorized representative as required 
under 45 CFR part 46 and 21 CFR 50 regulations, as applicable. 
 
VI. HIPAA Form of Authorization 
<<Insert name of external institution/investigator>> defers HIPAA Privacy Board 
Determinations to UIRB which may include a HIPAA authorization, a waiver of authorization, 
and/or use of a limited/de-identified data set. <<Insert name of external 
institution/investigator>> must abide by HIPAA determinations made by the UIRB and must 
submit any additional forms (e.g. Notice of Privacy Practices, Information for Accounting of 
Disclosures, etc.) as necessary. 
 
<<Insert name of external institution/investigator>> may use its own form of HIPAA 
authorization instead of the authorization language included in the University of Utah 
Consent Template. In this case, <<insert name of external institution/investigator>> will 
ensure that its form of authorization explicitly permits PHI to be used and shared by and 
with the University of Utah as necessary for reviewing and overseeing the research as 
specified in this agreement. Both the University of Utah and <<insert name of external 
institution/investigator>> are responsible for ensuring that information is shared in a HIPAA-
compliant manner.  
 
VII. Duties and Responsibilities of UIRB 
a. Review and Authority 
The UIRB will conduct initial and continuing reviews. The UIRB will approve consent 
forms for all sites. The UIRB will review amendments to approved protocols. The UIRB 
will review information which requires reporting (i.e. unanticipated problems involving 
risks to participants or others, non-compliance, protocol deviations, etc.) for all sites. 
 
The UIRB has the authority to suspend or terminate approval of research that is not 
being conducted in accordance with the UIRB policies, is not in compliance with Federal 
Regulations or that has been associated with unexpected serious harm to participants. 
 
 
VIII. Duties and Responsibilities of <<insert name of External Institution or 
Investigator>> 
a. Human Subject Research Guidance 




• The Belmont Report: Ethical Principles and Guidelines for the Protection of 
Human Subjects of Research (or other internationally recognized equivalent; see 
section B.1. of the Terms of the Federalwide Assurance (FWA) for International 
(Non-U.S.) Institutions);  
• The U.S. Department of Health and Human Services (HHS) regulations for the 
protection of human subjects at 45 CFR part 46 (or other procedural standards; 
see section B.3. of the Terms of the FWA for International (Non-U.S.) 
Institutions);  
• The FWA and applicable Terms of the FWA for the University of Utah; and  
• The relevant University of Utah policies and procedures for the protection of 
human subjects. 
The <<Insert name of external institution/investigator>> understands and accepts the 
responsibility to comply with the standards and requirements stipulated in the above 
documents and to protect the rights and welfare of human subjects involved in research 
conducted under this agreement. No subjects may be enrolled in research under this 
agreement prior to the research’s review and approval by the UIRB. 
b. Facilitated Review 
<<Insert name of external institution>> will conduct a facilitated review locally, 
according to their local policies. A facilitated review is the process by which <<insert 
name of external institution>> may accept and rely on the approval issued by the UIRB. 
Delete this section if a facilitated review is not conducted at the external institution or 
this agreement is with an individual external investigator.  
c. Investigator Responsibilities  
Investigators conducting research subject to this agreement are responsible for 
reviewing the PI Responsibilities and the PI Statement of Assurance (available on the 
UIRB website). Investigators must abide by the stipulations described in the Statement 
of Assurance. Investigators will agree to the Statement of Assurance when submitting a 
research protocol through the Electronic Research Integrity and Compliance 
Administration (ERICA) program.  
 
The PI is responsible for submitting the new study application and any subsequent 
continuing review applications. The PI is responsible for submitting amendments, report 
forms and the final project report, as applicable.  
d. Local oversight 
<<Insert name of external institution/investigator>> will maintain oversight for local 
unanticipated problems involving risks to participants or others and local non-
compliance.  
e. Authority to Audit 
<<Insert name of external institution>> retains authority to conduct audits to ensure 
compliance. Delete this section if this agreement is with an individual external 
investigator.  
f. Conflict of Interest 
<<Insert name of external institution>> is responsible for evaluating the potential 
financial conflicts of interest of its investigators and research staff, according to <<insert 
name of external institution>> policy. <<Insert name of external institution>> will report 
all financial conflicts to the UIRB. Delete this section if this agreement is with an 






IX. Duties and Responsibilities of both the UIRB and <<insert name of External 
Institution or External Investigator>> 
a. Federalwide Assurance 
Both the University of Utah and <<Insert name of external institution>> have FWAs and 
so agree to abide by all applicable regulations in the conduct of human subjects 
research at each facility. Delete this paragraph if the external institution does not have 
an FWA or this agreement is with an individual external investigator. 
b. Agreement on File 
Both the UIRB and <<insert name of external institution/investigator>> agree to keep 
this Reliance Agreement on file at the respective institution and made available upon 
request to OHRP or any U.S. federal department or agency conducting or supporting 
research to which the FWA applies. 
c. Policies and Procedures 
Both the UIRB and <<insert name of external institution/investigator>> agree to develop 
or maintain standard operating procedures consistent with this agreement.  
d. Communication and Cooperation 
Both the UIRB and <<insert name of external institution/investigator>> agree to 
maintain effective communication and cooperation mechanisms sufficient to ensure 
adequate protections for human research subjects. Both institutions agree to fully 
cooperate with the reciprocal IRB including providing relevant documentation and 
records as needed.   
e. Event Reporting  
Both the UIRB and <<insert name of external institution/investigator>> agree to 
promptly inform to the reciprocal institution of reports of serious or continuing 
noncompliance in the conduct of the study and unanticipated problems involving risks 
to participants or others, encountered in research as specified in this agreement.  
 
X. Notices and Primary Contacts 
a. Any notices to the undersigned institutional officials or correspondence regarding IRB 
review and oversight must be addressed as follows: 
 
If to UIRB: 
Thomas N. Parks, PhD 
Vice President for Research 
University of Utah 
201 South Presidents Circle, Room 210 






University of Utah 
75 South 2000 East, #111 









IRB Associate Director 
University of Utah 
75 South 2000 East, #111 





If to <<insert name of applicable external institutional official(s)/investigator>>: 










































































Richard Whitney Coleman, B.S.N., R.N., C.C.R.C., Mr. Coleman is 
the Program Director of the Collaborative Pediatric Critical Care 
Research Network (CPCCRN). Prior to this appointment, he was a 
Project Manager in the CPCCRN, managing large multicenter network 
projects.  He graduated from Johns Hopkins University in the Masters 
of Research Administration (MRA) program December 2017. His 
Bachelor’s degree comes from the University of Utah’s Nursing 
Program in 2010. Other work experience includes Clinical Research 
Coordinator with NeuroNEXT and years as a Clinical Research Nurse for 
the CTSA at the University of Utah. Whit is a recognized leader in 
clinical research at the University of Utah and has extended his 
leadership influence outside the university, through his support of 
NeuroNEXT and the CPCCRN. He is an effective public speaker and 
speaks nationally as an expert in rare diseases. He is fluent in Spanish. 
His clinical skills include ACLS and PALS certification and is 
knowledgeable in dealing with a diverse group of disease states in the 
research setting due to his diverse background and extensive 
experience on over 200 protocols. 
Mr. Coleman is responsible for day-to-day operations of the CPCCRN. 
Mr. Coleman interviews, hires, trains, mentors and supervises all 




teleconferences, prepares regular reports for the NICHD, and 
negotiates contracts as needed with central laboratories, pharmacies, 
and site monitoring companies. 
